| Justin Fuller, CRNP | |
|
70 Plaza Dr, Pell City, AL 35125-9314 | |
| (205) 814-9284 | |
| (205) 814-9626 |
| Full Name | Justin Fuller |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner - Family |
| Location | 70 Plaza Dr, Pell City, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013565613 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 1-131835 (Alabama) | Primary |
| Entity Name | Inri Medical Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831103837 PECOS PAC ID: 0749270197 Enrollment ID: O20040517000780 |
News Archive
The latest cardiovascular disease (CVD) prevention guidelines have been overhauled to produce a user friendly document with concise messages that awards greater weight than ever before to evidence from clinical trials and observational population studies. The "European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012)" - were launched at the EuroPRevent2012 meeting in Dublin, Ireland.
The September Policy Brief by Ricardo Rodrigues and Andrea Schmidt aims to present information on the current picture of public and private expenditure on long-term care for older people and to discuss the challenges of financing care. Moreover it provides preliminary results on potential redistribution effects of home care benefits (based on SHARE data).
Researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden, have discovered a previously unknown mechanism which helps intestinal bacteria to affect the formation of blood vessels. The results, which are presented in Nature, may provide future treatments of intestinal diseases and obesity.
PENTAX Medical Company, a healthcare industry leader in diagnostic and therapeutic endoscopy, announces the introduction of the C2 CryoBalloon Ablation System for the treatment of Barrett's esophagus, a condition in which the lining of the esophagus develops abnormal lesions primarily as a result of chronic gastroesophageal reflux disease.
Pharmasset, Inc. announced today that safety and pharmacokinetic data from the PSI-352938 single ascending dose study support progression to a multiple ascending dose trial with PSI-938, which has initiated dosing. PSI-938 is a guanine nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Justin Fuller, CRNP 70 Plaza Dr, Pell City, AL 35125-9314 Ph: (205) 814-9284 | Justin Fuller, CRNP 70 Plaza Dr, Pell City, AL 35125-9314 Ph: (205) 814-9284 |
News Archive
The latest cardiovascular disease (CVD) prevention guidelines have been overhauled to produce a user friendly document with concise messages that awards greater weight than ever before to evidence from clinical trials and observational population studies. The "European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012)" - were launched at the EuroPRevent2012 meeting in Dublin, Ireland.
The September Policy Brief by Ricardo Rodrigues and Andrea Schmidt aims to present information on the current picture of public and private expenditure on long-term care for older people and to discuss the challenges of financing care. Moreover it provides preliminary results on potential redistribution effects of home care benefits (based on SHARE data).
Researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden, have discovered a previously unknown mechanism which helps intestinal bacteria to affect the formation of blood vessels. The results, which are presented in Nature, may provide future treatments of intestinal diseases and obesity.
PENTAX Medical Company, a healthcare industry leader in diagnostic and therapeutic endoscopy, announces the introduction of the C2 CryoBalloon Ablation System for the treatment of Barrett's esophagus, a condition in which the lining of the esophagus develops abnormal lesions primarily as a result of chronic gastroesophageal reflux disease.
Pharmasset, Inc. announced today that safety and pharmacokinetic data from the PSI-352938 single ascending dose study support progression to a multiple ascending dose trial with PSI-938, which has initiated dosing. PSI-938 is a guanine nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection.
› Verified 8 days ago
Ms. Laura Paige Farris, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1508 Cogswell Ave, Pell City, AL 35125 Phone: 205-814-1526 | |
Wendy O'neal, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 41 Eminence Way Ste A, Pell City, AL 35128 Phone: 205-884-9000 | |
Erin Chrisla Martin, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 70 Plaza Dr, Pell City, AL 35125 Phone: 205-814-9284 Fax: 205-814-9626 | |
Angela K Belyeu, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 7067 Veterans Pkwy, Suite 130, Pell City, AL 35125 Phone: 205-884-9000 Fax: 205-884-8111 | |
Kelsie W Roulaine, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 74 Plaza Dr, Pell City, AL 35125 Phone: 205-814-9284 Fax: 205-814-9626 | |
Lisa Ellison, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 70 Plaza Dr, Pell City, AL 35125 Phone: 205-814-9284 Fax: 205-338-0865 |